Alternative strategies for vaccine development against avian flu

Michele A. Zacks, Slobodan Paessler

Research output: Chapter in Book/Report/Conference proceedingChapter


Intense focus has been placed on investigation of vaccine strategies that provide cross-protection against H5N1. In April of 2007, an inactivated influenza A/Vietnam/ 1203/04 (H5N1) vaccine developed by Sanofi-Aventi was approved by the U.S. Food and Drug Administration, despite its suboptimal efficacy profile. Nonetheless, other approaches to vaccine development are being tested, including recombinant subunit, viral vectored and plasmid DNA (pDNA) vaccines. This chapter will focus on several alternative H5N1 vaccines and therapeutic antibody approaches not covered in previous reviews: linear DNA vaccines, protein-based flagellin conjugate vaccines, and an alphavirus based vaccine approach. In addition, we describe some of the animal models potentially useful for testing the efficacy of the vaccine candidates against avian influenza.

Original languageEnglish (US)
Title of host publicationGlobal View of the Fight Against Influenza
PublisherNova Science Publishers, Inc.
Number of pages10
ISBN (Print)9781607419525
StatePublished - Jul 2009

ASJC Scopus subject areas

  • General Medicine
  • General Social Sciences


Dive into the research topics of 'Alternative strategies for vaccine development against avian flu'. Together they form a unique fingerprint.

Cite this